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Association between capsular serotype V and
macrolide resistance in group B Streptococcus
To the Editor
Group B Streptococcus (GBS) expresses a polysac-
charide antigen on its surface that is used for serotype
identification (serotypes Ia, Ib, II–IX). Serotyping can
be performed by use of a rapid latex agglutination test
or by polymerase chain reaction (PCR) analysis [1].
The serotype distribution of both invasive and col-
onizing GBS isolates is continuously evolving and
demonstrates not only regional, but also temporal
variation. Thus, we read with interest the article by
Morozumi et al. [2]. The authors investigated the sero-
types, the genetic diversity by multilocus sequence
typing, and the frequency of macrolide (ML) resist-
ance of GBS isolates responsible for invasive infec-
tions in neonates in Japan from 2006 to 2011.
Although their data add important information to epi-
demiological studies on GBS serotype distribution
worldwide, we kindly request further exploration of
their results on the frequency of serotype V.
Without intrapartum antimicrobial prophylaxis,
peripartum transmission to the newborn is estimated
to be 50–70% [3], resulting in a high frequency of
early-onset GBS sepsis. In previous studies, about
20% of GBS isolates found in colonized Japanese
women were designated as serotype V [4, 5]. However,
in the study by Morozumi et al. [2], the frequency of
serotype V isolates in 150 GBS isolates obtained from
invasive infections in neonates was zero.
We recently found a highly significant association
between serotype V and ML resistance in GBS-
colonized Swiss women [6]. This is in line with pre-
vious findings in the Asia, Europe and the United
States (Table 1 [6–19]). In the study by Morozumi
et al. [2], 7/32 (21·9%) serotype Ia and 24/88 (27·3%)
serotype III GBS isolates showed ML resistance. We
wonder whether the lack of serotype V GBS isolates
is an epidemiological variation in Japan, or alterna-
tively, whether it can be attributed to the ability of
GBS to switch capsular serotypes [20]. Recent studies
using genome analysis confirmed capsular switching
in serotype IV GBS isolates designated as clonal
complex (CC)17 and its variant (i.e. ST291) [15, 21],
even though CC17 GBS isolates are typically as-
sociated with serotype III. Such a phenomenon in
serotype V would be, to the best of our knowledge,
novel.
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Table 1. Association of macrolide resistance and serotype V
Ref. Study subjects Study period
Method of
serotyping
Total no.
of isolates
Serotype V
of all isolates,
n (%)
Macrolide resistance
in serotype V GBS
isolates, n (%)
Asia
Korea [7] NR 1990–1998 AGGL 185 16/185 (8·6%) 11/16 (68·8%)
Korea [8] NR 1990–2000 AGGL 308 45/308 (14·6%) 34/45 (75·6%)
Korea [9] NR 1990–2002 AGGL 446 94/446 (21·1%) 80/94 (85·1%)
Korea [10] PNW 2004–2007 AGGL 376 104/376 (27·7%) 85/104 (81·7%)
Europe
France [11] PNW NR AGGL, PCR 340 49/340 (14·4%) 11/49 (22·4%)
NN 119 6/119 (5%) 6/6 (100%)
AD 252 37/252 (14·7%) 15/37 (40·5%)
Germany [12] NN 1993–1997 EEM 193 12/193 (6·2%) 5/12 (41·7%)
AD 146 19/146 (13%) 5/19 (26·3%)
Italy [13] NN, AD 2002–2005 ID, PCR 91 14/91 (15·4%) 9/14 (64·3%)
Italy [14] PNW 2005–2006 AGGL 73 19/73 (26%) 2/19 (10·5%)
Ireland [15] AD, PNW, NN, INF 2007–2011 AGGL 177 30/177 (16·9%) 13/30 (43·3%)
Poland [16] AD, NN, INF 1996–2005 PCR–RFLP 114 20/114 (17·5%) 11/20 (55%)
Romania [17] AD, PNW 2009–2010 AGGL, PCR 148 40/148 (27%) 23/40 (57·5%)
Spain [18] NN 1992–2009 AGGL 212 14/212 (6·6%) 9/14 (64·3%)
Switzerland [6] PNW 2009–2010 AGGL, PCR 364 93/364 (25·5%) 24/93 (25·8%)
America
USA [19] NN, INF 1997–1999 NR 122 11/122 (9%) 8/11 (72·7%)
AD, Adults; AGGL, agglutination test; EEM, enzymatic extraction method; ID, immunodiffusion, INF, infants; NR, not
reported; NN, neonates; PCR, polymerase chain reaction; PNW, pregnant women; RFLP, restriction fragment length
polymorphism.
Countries in Europe are presented in alphabetical order. The list is not exhaustive.
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